References
- Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013–22.
- van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol. 2010;70:16–23.10.1111/bcp.2010.70.issue-1
- Food and Drug Administration. International conference on harmonisation; guidance on S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT Interval Prolongation) by human pharmaceuticals. Notice. Fed Regist. 2005;70:61133–4.
- U.S. Department of Health and Human Services. International Conference on Harmonisation (ICH). Guidance for Industry: E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005 [cited 2017 Feb 6]. Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf.
- Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, et al. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011;10:495–506.10.1038/nrd3501
- FDA alert: Information for Healthcare Professionals: Haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate). 2007 Sep [cited 2016 Jan 16]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085203.htm.
- European Medicines Agency (EMA): Review of domperidone-containing medicines, Annex I - List of the medicines affected by the referral, EMA/147415/2013 Rev 2. [cited 2016 Apr 1]. Available from: http://www.ema.europa.eu.
- McNaughton R, Huet G, Shakir S. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making. BMJ Open. 2014;4:e004221.10.1136/bmjopen-2013-004221
- Schachtele S, Tumena T, Gassmann KG, Fromm MF, Maas R. Implementation of warnings from Dear Doctor Letters (Rote-Hand-Briefe): an analysis of medication data from a large cohort of elderly patients. Dtsch Arztebl Int. 2014;111:255–63.
- Directive 2001/83/EC of the European Parliament and of the Council, article 107. 6 November 2001. [cited 2017 Mar 10]. Available from: http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf.
- European Medicines Agency: EudraVigilance. [cited 2016 Apr 4]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000679.jsp&mid=WC0b01ac05800250b5.
- U.S. Food and Drug Administration: FDA’s Adverse Event Reporting System. [cited 2016 Apr 5]. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm.
- Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf. 2009;18:512–8.10.1002/pds.1746
- Åström-Lilja C, Odeberg JM, Ekman E, Hägg S. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2008;17:587–92.10.1002/(ISSN)1099-1557
- Medical Dictionary for Regulatory Activities (MedDRA). [cited 2016 Apr 5]. Available from: http://www.meddra.org.
- Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. [cited 2016 Apr 5]. Available from: http://who-umc.org/Graphics/24734.pdf.
- WHO Collaborating Centre for Drug Statistics Methodology: ATC/DDD Index (online). 2014 [cited 2016 Apr 1]. Available from: http://www.whocc.no/atc_ddd_index.
- Arizona Center for Education and Research on Therapeutics (AZCERT). QT-drug lists by risk groups (online). 2016 [cited 2016 Oct 2]. Available from: http://www.crediblemeds.org.
- Vandael E, Vandenberk B, Vandenberghe J, Pincé H, Willems R, Foulon V. Incidence of Torsade de Pointes in a tertiary hospital population. [ Conference abstract: Belgian Heart Rhythm Meeting, Brussels, 2016 Oct 6–7].
- International Society of Drug Bulletins. Declaration of Berlin on Pharmacovigilance. Rev Prescrire. 2005;25:276–280.
- van der Hooft CS, Sturkenboom MC, van Grootheest K, Kingma HJ, Stricker BH. Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf. 2006;29:161–8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16454543.10.2165/00002018-200629020-00006
- Choo WK, Turpie D, Milne K, Davidson L, Elofuke P, Whitfield J, et al. Prescribers’ practice of assessing arrhythmia risk with QT-prolonging medications. Cardiovasc Ther. 2014;32:209–13.10.1111/cdr.2014.32.issue-5
- Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al. Prevention of Torsade de Pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2010;55:934–47.10.1016/j.jacc.2010.01.001
- Molokhia M, Pathak A, Lapeyre-Mestre M, Caturla L, Montastruc JL, McKeigue P. Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in Southwest France. Br J Clin Pharmacol. 2008;66:386–95.10.1111/bcp.2008.66.issue-3
- Rao P, Kowey PR. Drug-induced long-QT syndrome and Torsade de Pointes: an underrated problem? Europace. 2014;16:4–5.10.1093/europace/eut331
- Warnier M, Rutten F, Souverein P, Hoes A, de Boer A, De Bruin M. Are ECG monitoring recommendations before prescription of QT prolonging drugs applied in daily practice? the example of haloperidol. Pharmacoepidemiol Drug Saf. 2014;23:228–9.
- Roden DM. Taking the “idio” out of “idiosyncratic”: predicting Torsades de Pointes. Pacing Clin Electrophysiol. 1998;21:1029–34.10.1111/pace.1998.21.issue-5
- Johnston J, Pal S, Nagele P. Perioperative Torsade de Pointes: a systematic review of published case reports. Anesth Analg. 2013;117:559–64.10.1213/ANE.0b013e318290c380
- Woosley RL, Romero K. Assessing cardiovascular drug safety for clinical decision-making. Nat Rev Cardiol. 2013;10:330–7.10.1038/nrcardio.2013.57